$RGBP Regen BioPharma News Regen BioPharma, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
//Desmond//
$RGBP Regen BioPharma News

Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer

http://www.prnewswire.com/news-releases/regen...00026.html




SAN DIEGO, December 7, 2016 /PRNewswire/ --

Regen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in Guangzhou, China[1] have demonstrated that expression of NR2F6 in patients with early cervical cancer correlates with poor prognoses. These scientists tested for NR2F6 in patient's cervical cancer tissue as well as in the normal tissue surrounding each of their tumors.

"This is an interesting study and the first that I am aware of that has tested for NR2F6 in patients with cervical cancer," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen BioPharma, Inc. "What they found was that those patients who had high amounts of NR2F6 protein expressed in their tumors died much faster than those patients with low or no expression of NR2F6 protein. To me, this is an important validation of the role of NR2F6 in cancer in humans, rather than simply animal models, and implies that inhibiting NR2F6 may be beneficial for these patients. While the study didn't go into the mechanism of action, it did show clear correlation and statistical significance indicating that NR2F6 expression is a potential biomarker for early cervical cancer."

Regen BioPharma, Inc. is developing small molecule inhibitors and activators of NR2F6. Inhibitors (which inhibit the expression of NR2F6) are expected to be useful in the treatment of various cancers and activators (which activate the expression of NR2F6) in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.

"This journal article provides empirical evidence that supports our belief that inhibiting NR2F6 is a key to treating cancer in patients," noted David Koos, Regen's Chairman & CEO. "Our company sees an opportunity to enhance both the longevity and quality of life through further developing its NR2F6 small molecule therapies for treating cancer and autoimmune diseases."

Regen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted by Regen an exclusive worldwide right and license for the development and commercialization of NR2F6 intellectual property controlled by Regen for non-human veterinary therapeutic use. Controlling NR2F6 in dogs and cats may be effective in treating diseases such cancer and arthritis at the veterinary level.

Regen believes that, in addition to its human therapeutics which may be developed by Regen, licensing fees related to veterinary applications of NR2F6 which may be developed by Zander may provide an additional income stream to Regen.

Zander Therapeutics Inc. is a wholly owned subsidiary of Entest BioMedical Inc. (PINKS: ENTB). David R. Koos serves as Chairman and Chief Executive Officer of Regen, Entest Biomedical, Inc. and Zander Therapeutics.

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

About Zander Therapeutics Inc.:

Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by Entest BioMedical Inc. (a publicly traded company -- PINK: ENTB). Zander is primarily focused on developing small molecule therapies for treating autoimmune disorders and canine cancer (dogs). Currently the Company is developing products treating blood disorders using small molecules based on NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP), gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cell through its patent molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy treated cancer patients.

http://www.zandertherapeutics.weebly.com/

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

[1]Int. J. Mol. Sci. 2016, 17, 1694

CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com

SOURCE Regen BioPharma, Inc.
All of my posts are honest, opinion based statements from due diligence performed by myself.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CelluPro Earns Global Recognition with EXCiPACT Certification

Updated Category News Views 2

Breaking New Ground with EXCiPACT Certification Here's a tale unfolding in the high-stakes world of biotechnology—CelluPro, a standout in cell culture media, just snagged the EXCiPACT™ certification. This isn't just some fancy plaque for the wall. It's a stamp of approval that screams reliability in the global biomanufacturing supply scene. Why This Certification...

Continue Reading
Aluminum Refractory Market to Hit $2.73B by 2031

Updated Category News Views 5

Riding the Aluminum Refractory Wave to 2031 Look, when you want to throw some cash in a market that's gaining steam, aluminum refractory materials might not be your first pick. But here's the thing: it's charging ahead to a cool $2.73 billion by 2031. And if you're keeping tabs on the likes of RHI Magnesita and Calderys, this is a sector that deserves a once-over. What...

Continue Reading
Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Updated Category News Views 3

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Continue Reading
Thermoplastic Polyimide: A $0.86 Billion Market by 2032

Updated Category News Views 1

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Continue Reading
Nurminen Logistics Doubles Sweden–Italy Rail Capacity

Updated Category News Views 6

Nurminen Logistics Betting Big on Rail Expansion Feeling the pulse of the logistics world is much like trying to catch lightning in a bottle, but Nurminen Logistics seems to have found its rhythm. They're ramping up their services between Sweden and Italy, leveraging rail to push the envelope. Come October, they're doubling down from one to two weekly departures, giving...

Continue Reading
Early Orders Key for Custom Kids' Gifts This Season

Updated Category News Views 1

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Continue Reading
Indiana Fire Safety: The Importance of Regular Inspections

Updated Category News Views 3

Everybody thinks of fire extinguishers as those red cans hanging quietly on walls, but there's more to them than meets the eye. In Central Indiana, these devices are a literal lifeline, and neglecting their upkeep is playing with fire—literally. What Makes Monthly Checks a Big Deal? Fire extinguishers aren't just there for decoration. They're critical safety gear. This...

Continue Reading
U.S. Court Ruling Opens Market for Cocrystal's CrysQnol™

Updated Category News Views 9

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

Continue Reading
FOTON Accelerates Global Push with European Focus

Updated Category News Views 4

The Road to Global Dominance Ever feel like someone’s racing past you while others try to catch up? That’s FOTON in the relentless world of commercial vehicles. This juggernaut of a company isn't just satisfied with leading the pack; they’ve got their eyes set on redefines the game, especially with their new moves in Europe. A Shift in Strategy Right now, the...

Continue Reading
Huayan Robotics Hits IMTS 2026 with Cutting-Edge Tech

Updated Category News Views 2

Unveiling Robotics Prowess at IMTS 2026 Every two years, the world of manufacturing gathers at the International Manufacturing Technology Show (IMTS), and this time, the spotlight is on Huayan Robotics. With the event drawing over 90,000 professionals, everybody with a finger on the pulse of intelligent manufacturing will be keen to see what Huayan has up its sleeve. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Recycling Equipment: Market Growth Insights

Updated Category News Views 105

The Growing Recycling Equipment Market The Recycling Equipment Market is on a remarkable trajectory, with expectations to soar from USD 29.46 billion in 2023 to USD 48.07 billion by 2032. This promising growth reflects a compound annual growth rate (CAGR) of 5.59% between 2024 and 2032. A global awakening to environmental issues is driving industries and governments alike...

Continue Reading
Callinex Mines Expands Exploration Efforts at Pt. Leamington

Updated Category News Views 99

Callinex Mines Receives Exploration Permit for Point Leamington Project Callinex Mines Inc., a prominent player in the base and precious metals sector, has recently secured a two-year exploration permit for its Pt. Leamington Project. This exciting development comes as the company aims to enhance its mineral resource base, specifically targeting the rich deposits of gold,...

Continue Reading
Exploring Oncology's Rapid Evolution and Oncolytics' Potential

Updated Category News Views 102

Oncology Approvals and Their Impact The landscape of oncology treatment is undergoing a remarkable transformation. Regulatory bodies like the FDA are not only approving new drugs but actively reshaping the future of cancer therapies. Recently, we've witnessed a surge in approvals, with over 50 new oncology treatments being authorized, signifying a pivotal change in...

Continue Reading
Oportun Successfully Launches $425 Million Asset-Backed Notes

Updated Category News Views 139

Oportun's Latest $425 Million Financing Success Oportun has recently achieved a significant milestone by successfully issuing $425 million in asset-backed securities. This accomplishment highlights the company's continual growth and robust position in the financial services sector. Understanding the Transaction This transaction comprised revolving fixed-rate notes backed...

Continue Reading
Steep Decline in CEO Confidence Signals Economic Challenges

Updated Category News Views 206

Significant Drop in CEO Confidence in Recent Survey The Conference Board recently reported a dramatic decline in the Measure of CEO Confidence, reflecting a stark shift in the sentiment among business leaders. In Q2 2025, the metric plunged by 26 points to a mere 34, marking the lowest level since late 2022. This decline is notable as it represents the most significant...

Continue Reading